Prima BioMed (PRR)
Prima BioMed Ltd. is a biotechnology company, which engages in developing oncology therapies in the field of immunotherapy. Its lead product is IMP321, which involves in clinical development for the treatment of cancer indications. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
|Market Price at 17-11-2017||$0.02|
|Price to Earnings Ratio||-6.44|
|Market Capitalisation||$49.91 (million)|
|Return on Equity (ROE)||-35.17%|